Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Sung, You Me ^a   Xu, Xuehua ^a   Sun, Junfeng ^a   Mueller, Duane ^a   Sentissi, Kinza ^a   Johnson, Peter ^a   Urbach, Elana ^a   Seillier Moiseiwitsch, Françoise ^a   Johnson, Michael D ^a   Mueller, Susette C ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; HERMES ANTIGEN; MATRIX METALLOPROTEINASE 14; PROTEIN KINASE SYK; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER CELL; CANCER INHIBITION; CELL ANCHORAGE; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEPLETION; PROTEIN FUNCTION; PUBERTY; ANIMAL; BIOSYNTHESIS; CANCER INVASION; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; UDDER;

ANIMALS; ANTIGENS, CD44; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INTEGRIN ALPHA6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MATRIX METALLOPROTEINASE 14; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; PROTEIN-TYROSINE KINASES;

EID: 70449348605     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007445     Document Type: Article

References (47)

1. Coopman PJ, Mueller SC (2006) The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. Cancer Letters 241: 159-173.
2. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, et al. (2006) Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 66: 11187-11193.
3. Liu S, Ren S, Howell P, Fodstad O, Riker AI (2008) Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res.
4. Moroni M, Soldatenkov V, Zhang L, Zhang Y, Stoica G, et al. (2004) Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 64: 7346-7354.
5. Zhang X, Shrikhande U, Alicie BM, Zhou Q, Geahlen RL (2009) Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res 7: 634-644.
6. Li J, Sidell N (2005) Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase. Int J Cancer 117: 14-20.
7. Mahabeleshwar GH, Kundu GC (2003) Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3′-kinase activity in breast cancer cells. J Biol Chem 278: 6209-6221.
8. Ruschel A, Ullrich A (2004) Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells. Cell Signal 16: 1249-1261.
9. Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268.
10. Krause S, Maffini MV, Soto AM, Sonnenschein C (2008) A Novel 3D In Vitro Culture Model to Study Stromal-Epithelial Interactions in the Mammary Gland. Tissue Eng Part C Methods 14: 261-271.
11. Heppner GH, Miller FR, Shekhar PM (2000) Nontransgenic models of breast cancer. Breast Cancer Res 2: 331-334.
12. Turner M, Mee PJ, Costello PS, Williams O, Price AA, et al. (1995) Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 378: 298-302.
13. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, et al. (1995) Syk tyrosine kinase required for mouse viability and B-cell development. Nature 378: 303-306.
14. Abtahian F, Guerriero A, Sebzda E, Lu MM, Zhou R, et al. (2003) Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 299: 247-251.
15. Mueller SC, Artym VV, Kelly T (2008) Invadopodia: Interface for Invasion. In: Dylan E, Hoyer-Hansen G, Blasi F, Sloane BF, eds (2008) The Cancer Degradome - Proteases in Cancer Biology. New York: Springer. pp 403-432.
16. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC (2006) Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66: 3034-3043.
17. Sabeh F, Shimizu-Hirota R, Weiss SJ (2009) Protease-dependent versus - independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol 185: 11-19.
18. Artym VV, Yamada KM, Mueller SC (2009) ECM Degradation Assays for Analyzing Local Cell Invasion. Methods Mol Biol 522: 1-9.
19. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, et al. (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544.
20. Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk, et al. (2000) The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 406: 742-747.
21. Coopman PJ, Do MTH, Thompson EW, Mueller SC (1998) Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity. Clin Canc Res 4: 507-515.
22. Saltel F, Chabadel A, Bonnelye E, Jurdic P (2008) Actin cytoskeletal organisation in osteoclasts: A model to decipher transmigration and matrix degradation. Eur J Cell Biol 87: 459-468.
23. Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, et al. (2006) RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 25: 1456-1468.
24. Nakahara H, Nomizu M, Akiyama SK, Yamada Y, Yeh Y, et al. (1996) A mechanism for regulation of melanoma invasion, ligation of alpha6beta1 integrin by laminin G peptides. J Biol Chem 271: 27221-27224.
25. Fillmore C, Kuperwasser C (2007) Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 9: 303.
26. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, et al. (2008) The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53.
27. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, et al. (2008) Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13: 394-406.
28. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, et al. (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 185: 191-203.
29. Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, et al. (2006) Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene 25: 4975-4985.
30. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, et al. (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68: 989-997.
31. Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, et al. (1999) Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 112: 4615-4625.
32. Zhang X, Emerald BS, Mukhina S, Mohankumar KM, Kraemer A, et al. (2006) HOXA1 is required for E-cadherin-dependent anchorage-independent survival of human mammary carcinoma cells. J Biol Chem 281: 6471-6481.
33. Gilles C, Polette M, Coraux C, Tournier JM, Meneguzzi G, et al. (2001) Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. J Cell Sci 114: 2967-2976.
34. Akisaka T, Yoshida H, Suzuki R, Takama K (2008) Adhesion structures and their cytoskeleton-membrane interactions at podosomes of osteoclasts in culture. Cell Tissue Res 331: 625-641.
35. Gad A, Lach S, Crimaldi L, Gimona M (2008) Plectin deposition at podosome rings requires myosin contractility. Cell Motil Cytoskeleton 65: 614-625.
36. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, et al. (2004) NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114: 569-581.
37. Mandal S, Johnson KR, Wheelock MJ (2008) TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways. Exp Cell Res 314: 3478-3493.
38. Galliher AJ, Schiemann WP (2006) Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 8: R42.
39. Zhu Y, Herlaar E, Masuda ES, Burleson GR, Nelson AJ, et al. (2007) Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406. Toxicol Appl Pharmacol 221: 268-277.
40. Masuda ES, Schmitz J (2008) Syk inhibitors as treatment for allergic rhinitis. Pulm Pharmacol Ther 21: 461-467.
41. Turner M, Gulbranson-Judge A, Quinn ME, Walters AE, MacLennan IC, et al. (1997) Syk tyrosine kinase is required for the positive selection of immature B cells into the recirculating B cell pool. J Exp Med 186: 2013-2021.
42. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, et al. (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086.
43. Miller FR (1996) Models of progression spanning preneoplasia and metastasis: the human MCF10AneoT.TGn series and a panel of mouse mammary tumor subpopulations. Cancer Treat Res 83: 243-263.
44. Miller FR, Santner SJ, Tait L, Dawson PJ (2000) MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 92: 1185-1186.
45. Bebu I, Mathew T (2008) Comparing the means and variances of a bivariate log-normal distribution. Stat Med 27: 2684-2696.
46. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3. Epub;%2004 Feb 12.: Article3.
47. Benjamini JA, Hochman J (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 57: 289-300.